Voice your opinion on congressional bill S340-116 and let lawmakers know your stance with UnPac!

Main Subject: Health

Creating and Restoring Equal Access to Equivalent Samples Act of 2019 or the CREATES Act of 2019

This bill generally allows the developer of a drug or biological product, such as a generic or biosimilar version of a drug, to bring a civil action against the license holder of an approved medication if the holder refuses to make available sufficient quantities of the approved medication for the developer's testing. The bill also establishes affirmative defenses to such a civil action.

In addition, the bill authorizes drug manufacturers seeking Food and Drug Administration approval for a generic drug to use alternative methods to develop elements assure safe use of a drug.

HR2700-116, HR965-116,

Senate Actions

Calendars
Feb. 06 2019	Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 22.
Feb. 05 2019	Introduced in the Senate. Read the first time. Placed on Senate Legislative Calendar under Read the First Time. (Sponsor introductory remarks on measure: CR S868-869)

Library of Congress Actions

IntroReferral
Feb. 05 2019	Introduced in Senate

Senate bill S340-116

A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.

Senate bill S340-116

A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.

Promote the cause!

Or use this QR code